Crossmark

Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma—Polish Lymphoma Research Group real-life analysis

Crossref DOI link: https://doi.org/10.1016/j.pharep.2019.02.001

Published Print: 2019-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Długosz-Danecka, Monika

Hus, Iwona

Puła, Bartosz

Jurczyszyn, Artur

Chojnacki, Tomasz

Blajer-Olszewska, Beata

Drozd-Sokołowska, Joanna

Raźny, Małgorzata

Romejko-Jarosińska, Joanna

Taszner, Michał

Jurczak, Wojciech
License Information

Text and Data Mining valid from 2019-06-01
More Information

This article is maintained by: Elsevier

Article Title: Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma—Polish Lymphoma Research Group real-life analysis

Journal Title: Pharmacological Reports

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.pharep.2019.02.001

Content Type: article

Copyright: © 2019 Published by Elsevier B.V. on behalf of Institute of Pharmacology, Polish Academy of Sciences.

Document is current

Any future updates will be listed below